MAPT and Alzheimer disease: Since sporadic AD is not detected before the appearance of the first clinical symptoms, the strategy that we are proposing can benefit from the number of reliable biomarkers such as cerebrospinal fluid (CSF) levels of tau and Aβ and neuroimaging, especially with tau and Aβ tracers developed recently in the field.